Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population.

Deitelzweig SB, Buysman E, Pinsky B, Lacey M, Jing Y, Wiederkehr D, Graham J.

Clin Ther. 2013 Aug;35(8):1201-10. doi: 10.1016/j.clinthera.2013.06.005. Epub 2013 Jul 16.

PMID:
23867114
2.

Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.

Spivey CA, Qiao Y, Liu X, Mardekian J, Parker RB, Phatak H, Claflin AB, Kachroo S, Abdulsattar Y, Chakrabarti A, Wang J.

J Manag Care Spec Pharm. 2015 Jul;21(7):596-606.

3.

Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population.

Deitelzweig SB, Pinsky B, Buysman E, Lacey M, Makenbaeva D, Wiederkehr D, Graham J.

Clin Ther. 2013 Oct;35(10):1536-45.e1. doi: 10.1016/j.clinthera.2013.08.013. Epub 2013 Sep 26.

PMID:
24075151
4.

The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.

Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ.

J Manag Care Pharm. 2013 May;19(4):302-16.

5.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

6.

Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system.

Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O.

Curr Med Res Opin. 2005 Oct;21(10):1583-94.

PMID:
16238898
7.

Stroke associated with discontinuation of warfarin therapy for atrial fibrillation.

Spivey CA, Liu X, Qiao Y, Mardekian J, Parker RB, Phatak H, Masseria C, Kachroo S, Abdulsattar Y, Wang J.

Curr Med Res Opin. 2015 Nov;31(11):2021-9. doi: 10.1185/03007995.2015.1082995. Epub 2015 Sep 21.

PMID:
26390258
8.

Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.

Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):567-74. doi: 10.1161/CIRCOUTCOMES.113.000192. Epub 2013 Aug 6. Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e59.

9.

Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.

Boccuzzi SJ, Martin J, Stephenson J, Kreilick C, Fernandes J, Beaulieu J, Hauch O, Kim J.

Curr Med Res Opin. 2009 Dec;25(12):2853-64. doi: 10.1185/03007990903196422.

PMID:
19916729
10.
11.

Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry.

Wang C, Yang Z, Wang C, Wang Y, Zhao X, Liu L, Wang DZ, Li H, Wang Y.

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1157-63. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.006. Epub 2013 Dec 2.

PMID:
24291013
12.

International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.

Nelson WW, Desai S, Damaraju CV, Lu L, Fields LE, Wildgoose P, Schein JR.

Curr Med Res Opin. 2014 Dec;30(12):2437-42. doi: 10.1185/03007995.2014.957822. Epub 2014 Sep 2.

PMID:
25170587
13.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
14.

Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.

Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L.

Am J Geriatr Pharmacother. 2009 Jun;7(3):159-66. doi: 10.1016/j.amjopharm.2009.06.002.

PMID:
19616184
15.

The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation.

Simon TA, Pan X, Kawabata H, Huang HY, Azoulay L.

Cardiovasc Ther. 2016 Apr;34(2):94-9. doi: 10.1111/1755-5922.12174.

17.

Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?

Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Curr Med Res Opin. 2014 Aug;30(8):1521-8. doi: 10.1185/03007995.2014.916159. Epub 2014 May 2.

PMID:
24758611
18.

Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation.

Song X, Sander SD, Varker H, Amin A.

Am J Cardiovasc Drugs. 2012 Aug 1;12(4):245-53. doi: 10.2165/11632540-000000000-00000.

PMID:
22775446
19.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570

Supplemental Content

Support Center